12/1 Business Wire Health: Oncology News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Business Wire Health: Oncology News - Health: Oncology News Distributed by Business Wire BackOffice Associates Announces Expanded Lineup At BackOffice Serving for a Cure To Benefit the Thomas Blake Sr. Memorial Fund November 30, 2009 at 6:44 pm SOUTH HARWICH, Mass.--(BUSINESS WIRE)--BackOffice Associates, LLC, the leader in data migration, data governance solutions, in support of SAP® solutions, today announced an expanded lineup for BackOffice Associates Serving For A Cure with James Blake tennis exhibition to benefit the Thomas Blake Sr., Memorial Research Fund, established to support cancer research at Memorial Sloan-Kettering Cancer Center. The event will take place, Tuesday, December 1st, with a VIP Reception at 5:30 pm, foll Media Files ViewMedia?mgid=196481&vid=2 (2 KB) Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) Mourns Loss of Frederick Joseph November 30, 2009 at 6:21 pm NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) are deeply saddened by the loss of MMRF and MMRC Board Member and dear friend Frederick Joseph. He passed on November 27, 2009, following a courageous battle with multiple myeloma, an uncommon and incurable blood cancer. “Fred was one of the most heroic and inspirational individuals I have known. We will miss his sage advice, his thoughtful guidance, and his endu Media Files ViewMedia?mgid=206559&vid=2 (2 KB) ChemGenex to Present Positive Data for Omapro™ From Multiple Clinical Trials at ASH November 30, 2009 at 5:30 pm MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana. Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center will present VELCADE® (Bortezomib) for Injection to be Featured in Plenary Session at American Society of Hematology November 30, 2009 at 3:19 pm CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced nearly 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematology (ASH) being held December 5–8, 2009 in New Orleans, Louisiana. These abstracts include an oral presentation of data on successful VELCADE utilization in both induction and maintenance in the front-line setting during the distinguished plenary session being held on Sunday, December 6. T Media Files ViewMedia?mgid=179318&vid=2 (2 KB) Former Red Sox Player Mike Andrews to Retire as Jimmy Fund Chairman November 30, 2009 at 12:08 pm BOSTON--(BUSINESS WIRE)--After more than 30 years as chairman of Dana-Farber Cancer Institute’s Jimmy Fund, Mike Andrews, 66, will retire at the end of this year. Under his direction, the Jimmy Fund has grown from raising $1 million year to help further pediatric and adult cancer care and research to more than $64 million in Fiscal 2009. Andrews’ connection with the Jimmy Fund began as a rookie Red Sox second baseman on the 1967 “Impossible Dream” team when he met the fir Media Files ViewMedia?mgid=206521&vid=2 (2 KB) TravelCenters of America LLC Donates Over $440,000 to St. Jude's November 30, 2009 at 12:07 pm WESTLAKE, Ohio--(BUSINESS WIRE)--TravelCenters of America LLC through its TA and Petro branded locations nationwide raised $446,373 for the children of St. Jude Children’s Research Hospital® in October through the 16th annual Halloween Pumpkin Promotion. During the promotion, employees at participating TravelCenters of America (TA) and Petro Stopping Centers asked patrons to make a $1 donation to St. Jude to support its fight against catastrophic childhood diseases. Customers could ma Media Files ViewMedia?mgid=186751&vid=2 (2 KB) Sunshine Biopharma, Inc. Announces New Trading Symbol November 30, 2009 at 9:00 am MONTREAL--(BUSINESS WIRE)--Sunshine Biopharma, Inc., (OTCBB: MWBN) today announced that the trading symbol for its common stock has changed to “SBFM”effective immediately. Sunshine Biopharma is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company’s lead compound, Difluoro-Etoposide™, is a multi-purpose anti-tumor compound that is expected to enter Phase I clinical trials in C MagForce Nanotechnologies AG Applies for European Regulatory Approval of Its Nano-Cancer® Therapy November 30, 2009 at 8:30 am BERLIN--(BUSINESS WIRE)--MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products. With this step, MagForce has now commenced the conformity assessment procedure for its Nano-Cancer ® therapy. Following successful completion of this conformity assessment procedure and EC type testing of the magnetic field applicator, MagForce will be a Media Files ViewMedia?mgid=198147&vid=2 (2 KB) Lifeline Biotechnologies Reports on an Update to the First Warning System's™ Advanced Analytical Capabilities November 30, 2009 at 8:30 am RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today reported that management has recently returned from Singapore where meetings were conducted with Nanyang Technological University’s (NTU) School of Mechanical & Aerospace Engineering to receive the final report on the software development of Lifeline’s First Warning System™. Jim Holmes, Lifeline’s CEO said, “This final report is the result of a two year contract we’ve had Imaging e-Ordering Coalition Adds Five New Member Organizations to Promote Medically Appropriate Diagnostic Imaging Tests for All Patients November 30, 2009 at 8:00 am CHICAGO--(BUSINESS WIRE)--The Imaging e-Ordering Coalition (The Coalition) has added five new member organizations to its rapidly growing roster of leading healthcare providers, technology companies and diagnostic imaging organizations. The Coalition works to promote Health Information Technology (HIT) enabled decision-support (e-Ordering) as a solution to assure that all patients receive the most medically appropriate diagnostic imaging test for their specific condition. Members include: Americ Spectrum Pharmaceuticals Announces Completion of Enrollment in One Apaziquone Phase 3 Pivotal Trial for Bladder Cancer Ahead of Schedule November 30, 2009 at 7:00 am IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year. “This is a particularly important milestone for Spectrum and our clinical sites for their unprecedented and remarkabl Media Files ViewMedia?mgid=145348&vid=2 (2 KB)   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.